Company Overview
Pomdoctor Limited operates through its subsidiaries to provide an online B2C portal dedicated to the sale of pharmaceutical products, while simultaneously developing an online medical services platform specifically designed for chronic disease management within China. Operating within the Healthcare sector as a Pharmaceutical Retailer, the company focuses its strategic efforts on chronic disease management and pharmaceutical services, offering a dedicated platform for medical interventions. The company currently maintains a market capitalization of $29.50M and employs 156 individuals to execute its business operations across the Chinese market. These valuation and revenue figures indicate that Pomdoctor is a small-cap entity with a market cap significantly lower than its trailing twelve-month revenue of $366.86M, suggesting a distinct capitalization structure relative to its annual sales volume.
Financial Health
The company reported revenue of $366.86M over the trailing twelve months, yet posted a net income loss of $-148,901,728 and an EBITDA of $-25,949,008. The substantial disparity between the positive revenue figure of $366.86M and the negative net income reveals a cost structure where expenses, including cost of goods sold and operating costs, heavily outweigh gross profits, resulting in a net loss that is more than five times the EBITDA loss. Free cash flow stands at $-12,435,489, which indicates that the company is consuming cash to fund its operations and growth initiatives rather than generating excess liquidity for debt repayment or shareholder returns. This negative cash flow position limits financial flexibility, requiring the company to rely on existing cash reserves or external financing to meet its obligations. The company holds $5.75M in cash against $456.02M in debt, creating a leverage situation where debt obligations are nearly 80 times the available liquid assets. The debt-to-equity ratio is listed as N/A, likely due to the negative equity derived from the significant losses, which complicates standard leverage analysis. Profitability metrics are severely strained, with a gross margin of 14.1%, an operating margin of -6.5%, and a profit margin of -40.6%, indicating that the company retains only a small fraction of revenue after direct costs and loses over 40% of revenue after all expenses. The current ratio is 0.17, a figure well below the standard 1.0 threshold, indicating that the company's current assets are insufficient to cover its current liabilities without liquidating long-term assets or raising new capital. Return on Equity is N/A, reflecting the negative shareholders' equity, while Return on Assets stands at -32.6%, revealing that the company's assets are generating negative returns on an annualized basis.
Valuation Assessment
Trailing P/E and forward P/E ratios are both N/A due to the company's negative earnings over the trailing twelve months, which implies that traditional earnings-based valuation models cannot be applied to assess the trajectory of expected earnings in the near term. The price-to-book ratio is -0.03, a negative figure that indicates the market capitalizes the company at a value below its book value, often seen in distressed or unprofitable firms where the market assigns a negative premium to assets. The price-to-sales ratio is 0.08, suggesting that the market values the company at less than 10% of its annual sales, while the EV/EBITDA ratio of -87.40 further underscores the extreme leverage and lack of earnings generation relative to enterprise value. The stock has traded between a 52-week low of $0.19 and a 52-week high of $6.43, representing a massive range of volatility. Without a specific current price provided in the available facts to calculate the exact percentage position within the range, the valuation metrics suggest a market that has not yet assigned a sustainable multiple to the company's revenue stream. The beta value is N/A, meaning that data on the company's price volatility relative to the broader market index is not available in the provided financial data.
Growth & Income
Revenue growth over the last year stands at 16.2%, indicating a significant expansion in top-line sales, whereas earnings growth is N/A because the company is currently unprofitable. The absence of positive earnings growth data implies that the company is prioritizing top-line expansion over immediate profitability, a common strategy for pharmaceutical retailers in developing markets, but one that carries significant risk if cost control does not improve. As a non-dividend payer, the company distributes no dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company retains all of its limited earnings (or losses) rather than distributing income to shareholders. This retention of earnings suggests a strategy of reinvesting capital back into the business, potentially to fund the development of its online medical services platform or to reduce its substantial debt load of $456.02M.